Abstract
Traditionally, regression and recurrence following prostate cancer treatment have been screened by rising PSA, biopsy, and other biomarkers. Imaging provides an accurate alternative or complement to these conventional methods by depicting anatomic and functional images.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Green MM, Hiley CT, et al. Expression of vascular endothelial growth factor in locally invasive prostate cancer is prognostic for radiotherapy outcome. Intl J Radiat Oncology Biol Phys. 2007;67(1):84–90.
Sartor O. Endpoints in prostate cancer clinical trials. Urology. 2002;60 Suppl 1:101–7.
Sauvain JL, Palascak P, Nader N. Power Doppler imaging and prostate cancer: optional or necessary technique? [translated from French]. J Radiol. 2006;87(9):1063–72.
Sonn GA, Nataraian S, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013;189(1):86–91.
Turkbey B, Mani H, et al. Correlation of MRI tumor volume with histopathology. J Urol. 2012;188(4):1157–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bard, R.L. (2014). Imaging Detection of Regression and Recurrence. In: Bard, R., Fütterer, J., Sperling, D. (eds) Image Guided Prostate Cancer Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40429-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-40429-0_17
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40428-3
Online ISBN: 978-3-642-40429-0
eBook Packages: MedicineMedicine (R0)